Markets:

Overview

News

Currencies

International

Treasuries

Biogen Idec (NQ:BIIB)

169.91 -2.19 (-1.27%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 18, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

56 57 Next >

Tech Stocks Get Netflix Boost Amid Jittery Wider Market On Friday, Dow Stares At 4th Straight Loss ↗

January 20, 2023

U.S. stocks look set for a positive start on Friday, reversing course from the sell-off seen in the past three sessions. What Happened: Traders may have to contend with Fed speeches and housing market...

Via Benzinga

FDA Rejects Eli Lilly's Donanemab For Alzheimer's Disease, Needs More Data ↗

January 20, 2023

Via Benzinga

$100 Invested In Biogen 20 Years Ago Would Be Worth This Much Today ↗

January 19, 2023

Via Benzinga

Why Biogen's Stock Isn't Soaring Since Its Alzheimer's Drug Got Approval ↗

January 19, 2023

The Food and Drug Administration authorized Leqembi under an accelerated approval pathway this month.

Via The Motley Fool

If You Invested $25,000 in Biogen in 2018, This Is How Much You Would Have Today ↗

January 19, 2023

The stock hasn't been a great investment in recent years, but there's hope for a brighter future.

Via The Motley Fool

1 Large-Cap Biotech Stock to Buy for 2023 and Beyond ↗

January 03, 2023

This company's best asset may be its pipeline.

Via The Motley Fool

Is Biogen's Stock Too Risky to Invest in? ↗

December 28, 2022

Even at a discount, investors may be taking on a big risk with Biogen.

Via The Motley Fool

Neurodegenerative Diseases Focused Company Goes Public Via Wilbur Ross-Backed SPAC, Joins Alzheimer's Race To Compete Biogen ↗

January 18, 2023

Via Benzinga

This Monumental Breakthrough Could Turn the World Upside Down -- and Make Some Investors Filthy Rich ↗

January 17, 2023

The fountain of youth might not be a myth in the future.

Via The Motley Fool

Elliott Wave Technical Analysis: Biogen Inc. ↗

January 13, 2023

We are looking for further downside into wave C which could take us back to the area of wave 4.

Via Talk Markets

1 Hot Growth Stock to Buy Now, and 1 to Avoid ↗

January 11, 2023

One company is gearing up for further growth while the other stumbles over itself.

Via The Motley Fool

Biotech Bonanza: 2023 Biotech Outlook As The Fed Remains Hawkish ↗

January 11, 2023

2023 can be the year of biotechs after two consecutive years of negative or barely positive returns.

Via Talk Markets

Should You Buy Biogen Stock After Its Latest Alzheimer's Disease Drug Approval? ↗

January 10, 2023

There's more to the story with Biogen after receiving good news for Leqembi.

Via The Motley Fool

Barron's Top Weekend Stock Picks: Tesla, Snowflake, Delta And Why Warren Buffett's Berkshire Hathaway May Be In For Big Tax Bill ↗

January 07, 2023

Benzinga reviews this weekend's top stories covered by Barron's, here are the articles investors need to read.

Via Benzinga

Longeveron Shares Surge Following FDA Decision on Biogen Alzheimer's Drug ↗

January 06, 2023

Shares of Longeveron (NASDAQ: LGVN) are trading 5.37% higher amid strength in Alzheimer's-related stocks after the FDA granted accelerated approval to Biogen (NASDAQ: BIIB)'s Leqembi.

Via Benzinga

SAVA, LLY, IBB: Why These Alzheimer's Related Stocks Are Volatile On Friday ↗

January 06, 2023

Stocks of companies with Alzheimer's candidates, including Cassava Sciences, Inc. (NASDAQ: SAVA) and Eli Lilly And Company (NYSE: LLY), spiked on Friday after the FDA granted accelerated approval to

Via Benzinga

FDA Approves Biogen's Second Alzheimer's Treatment Under Accelerated Pathway ↗

January 06, 2023

Via Benzinga

Lecanemab Alert: What Would Alzheimer’s Drug Approval Mean for Biogen (BIIB) Stock? ↗

January 06, 2023

Biogen is in focus today with the company's lecanemab drug set for an FDA decision on approval, leading to bullish bets on BIIB stock.

Via InvestorPlace

Top Picks For 2023: Anavex Life Sciences ↗

January 06, 2023

Anavex is a biopharmaceutical company dedicated to the development of novel drug candidates to treat central nervous system diseases, with encouraging results in Alzheimer’s, Parkinson’s, and Rett...

Via Talk Markets

10 Health Care Stocks With Whale Alerts In Today's Session ↗

January 06, 2023

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Biogen Could Get A Second Alzheimer's OK — But Will Wild Card Medicare Bite? ↗

January 06, 2023

CMS already snubbed Biogen's first Alzheimer's drug. Will the second fare better?

Via Investor's Business Daily

1 Stock Defying the Downturn to Buy, and 1 to Avoid ↗

January 06, 2023

These two stocks might go in different directions in the future.

Via The Motley Fool

CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks ↗

January 06, 2023

Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too.

Via Investor's Business Daily

Could Eli Lilly Stock Help You Become a Millionaire? ↗

January 05, 2023

Over the past 10 years, when including its dividend, Eli Lilly's total return has amounted to an incredible 843%.

Via The Motley Fool

Biogen Names Priya Singhal as Executive Vice President, Head of Development

January 05, 2023

From Biogen Inc.

Via GlobeNewswire

Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies

January 04, 2023

From Biogen Inc.

Via GlobeNewswire

What's Going On With Biogen Stock Today? ↗

December 29, 2022

Biogen Inc (NASDAQ: BIIB) shares traded higher Thursday morning before pulling back. Reports indicate that the FDA's process for approving Biogen's Alzheimer's drug Aduhelm was filled with...

Via Benzinga

The Battles Brewing That Could Stoke Already Red-Hot Eli Lilly Stock ↗

December 28, 2022

Investors are closely watching two key spaces that could spark Lilly stock.

Via Investor's Business Daily

The Top Three Stocks Analysts Say To Buy

December 28, 2022

The analysts are rewarding companies that prove they can succeed in the face of headwinds and the most upgraded in Q4 2022 are Netflix, Biogen and Nike.

Via MarketBeat

Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors ↗

December 27, 2022

Biopharma stocks were not immune to the broader market downturn seen for much of 2022.

Via Benzinga

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

56 57 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.